FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered the application of a combination of a PDE5 inhibitor and testosterone ("Lybrido") for making a drug for female sexual dysfunction where the PDE5 inhibitor and testosterone are introduced in such a manner that the PDE5 inhibitor has an effect in 3.5-5.5 hours after the introduction of testosterone (versions) and an appropriate kit with the composition of testosterone for its immediate release on a target site, the specified kit in addition contains a package leaflet for the pharmaceutical composition containing testosterone taken 3.5-5.5 hours prior to perspective sexual activity and the pharmaceutical composition containing the PDE5 inhibitor taken 1-2 hours prior to perspective sexual activity.
EFFECT: higher vaginal pulsation amplitude and improved subjective sexual excitement as an effect of the combination.
22 cl, 5 dwg
